Pure Bioscience, Inc. (PURE) stock
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience, Inc. grew revenue 5.3% to $2.32M over the twelve months to Jul 31, 2026. At the latest close the market valued the company at $8.67M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $8.67M
- P/E ratio
- –
- Price to sales
- 3.75
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.32M
- Net income
- -$2.48M
- EPS, diluted
- -$0.02
- Book value per share
- -$0.05
- Diluted shares
- 131M
Trading
- Next earnings
- Dec 14, 2026 (estimated, during market hours)
- Previous close
- $0.08
- Open
- $0.07
- Day's range
- $0.07 – $0.07
- Volume
- 25,249
- Average volume (20 days)
- 43,915
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PURE | S&P 500 | Difference | PURE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.6% | +0.6% | −6.2 pts | ||
| 3 months | +2.2% | +3.4% | −1.2 pts | ||
| Year to date | +57.4% | +13.3% | +44.1 pts | ||
| 1 year | -13.0% | +16.6% | −29.6 pts | ||
| 3 years | -39.9% | +86.4% | −126.3 pts | -15.6% | +23.1% |
| 5 years | -83.1% | +81.9% | −164.9 pts | -29.9% | +12.7% |
| 10 years | -93.8% | +318.9% | −412.6 pts | -24.2% | +15.4% |
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pure Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Pure Bioscience
Miscellaneous Chemical Products
PURE Bioscience, Inc. develops and commercializes antimicrobial products designed to address pathogen and hygienic control challenges across various industries. Its core technology platform utilizes patented silver dihydrogen citrate (SDC), an electrolytically generated stabilized ionic silver molecule. The company's primary products include PURE Hard Surface, an EPA-registered disinfectant and sanitizer for food contact surfaces, and PURE Control, an FDA-approved direct food contact processing aid for poultry and produce. Additionally, it sells multi-purpose cleaners and SILVÉRION, an SDC-based raw material ingredient used in personal care formulations. PURE Bioscience markets its offerings directly and through third-party distributors to food processing plants, food service and restaurant operations, hospitality businesses, healthcare facilities, and commercial buildings.
Company profile, executives and historyPure Bioscience stock: common questions
What is Pure Bioscience's stock price?
PURE closed at $0.07 on Oct 19, 2026, down 12.10% on the day.
What is Pure Bioscience's market cap?
Pure Bioscience was worth $8.67M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PURE's P/E ratio?
Pure Bioscience lost money over the twelve months to Jul 31, 2026 (diluted EPS -$0.02), so it has no meaningful P/E ratio.
How much revenue does Pure Bioscience make?
Pure Bioscience reported revenue of $2.32M for the twelve months to Jul 31, 2026, up 5.3% from a year earlier.
Does Pure Bioscience pay a dividend?
No. Pure Bioscience has not paid a cash dividend over the last twelve months.
When does Pure Bioscience report earnings next?
Pure Bioscience is expected to report Q1 FY2027 results on Dec 14, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has PURE stock performed over the past year?
Including dividends, PURE returned -13.0% over the past year, against +16.6% for the S&P 500.
Who are Pure Bioscience's competitors?
Companies most similar to Pure Bioscience by business, industry and size include TOMZ, FSI, BLGO, SNES, CITR.
See a number that looks wrong?